TABLE 2.
Plasmids used in this study
| Plasmid | Characteristicsa | Reference |
|---|---|---|
| pMUTIN2 | Ampr Eryr | 43 |
| pMEH1 | ΔyvqI::pMUTIN2 Ampr Eryr | This study |
| pMEH2 | ΔyvqH::pMUTIN2 Ampr Eryr | This study |
| pMEH3 | ΔyvqF::pMUTIN2 Ampr Eryr | This study |
| pMEH4 | ΔyvqE::pMUTIN2 Ampr Eryr | This study |
| pMEH5 | ΔyvqG::pMUTIN2 Ampr Eryr | This study |
| pMEH6 | ΔyvcR::pMUTIN2 Ampr Eryr | This study |
| pMEH7 | ΔyvcS::pMUTIN2 Ampr Eryr | This study |
| pMEH8 | ΔyxaH::pMUTIN2 Ampr Eryr | This study |
| pHT315 | pUC19 derivative; Ampr Eryr | 2 |
| pMEH9 | yvqIH::pHT315 Ampr Eryr | This study |
| pMEH10 | yvqGFE::pHT315 Ampr Eryr | This study |
| pMEH11 | yvcRS::pHT315 Ampr Eryr | This study |
| pMEH12 | yxaGH::pHT315 Ampr Eryr | This study |
| pSac-Kan | pUC18 derivative; Ampr Kanr | 28 |
| pMEH4s | SP4-nisFEGI-lacZ::pSac-Kan Ampr Kanr | This study |
| pMEH5s | SP5-nisFEGI-lacZ::pSac-Kan Ampr Kanr | This study |
| pMEH13s | SP13-nisFEGI-lacZ::pSac-Kan Ampr Kanr | This study |
| pMEH46s | SP46-nisFEGI-lacZ::pSac-Kan Ampr Kanr | This study |
a
Ampr, ampicillin resistant; Eryr, erythromycin resistant; Kanr, kanamycin resistant; SP4, SP5, SP13, and SP46, synthetic promoters from the SPL.